


(19)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets



(11) **EP 1 090 635 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
11.04.2001 Bulletin 2001/15

(51) Int. Cl.⁷: **A61K 31/192**

(21) Application number: 00120170.6

(22) Date of filing: 22.09.2000

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.09.1999 JP 26846199
31.07.2000 JP 2000230463

(71) Applicant: **Kao Corporation**
Tokyo 103-8210 (JP)

(72) Inventors:
• **Suzuki, Atsushi**
Ichikai-machi, Haga-gun 321-3497 (JP)
• **Ochiai, Ryuji**
Ichikai-machi, Haga-gun 321-3497 (JP)
• **Tokimitsu, Ichiro**
Ichikai-machi, Haga-gun 321-3497 (JP)

(74) Representative: **HOFFMANN - EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **Use of ferulic acid for treating hypertension**

(57) A method for treating hypertension, a cardiac disease, or a cerebrovascular disease comprising administration of ferulic acid or a salt thereof, to a subject in need of treatment. Ferulic acid or salt thereof itself may be used as the only active antihypertensive ingredient in a therapeutic composition of the present invention. Alternatively, the therapeutic composition may comprise a diglyceride composition in combination with at least one compound selected from ferulic acid, a salt thereof and a ferulic ester.

EP 1 090 635 A2

Description

BACKGROUND OF THE INVENTION5 Field of the Invention:

[0001] The present invention is directed to methods of treating diseases such as hypertension using ferulic acid compounds. It also relates to compositions, such as fat compositions, comprising a ferulic acid compound and a diglyceride composition.

10 Description of the Background Art:


[0002] Hypertension is correlated with cardiac diseases such as angina pectoris, myocardial infarction and heart failure. It also is associated with cerebrovascular diseases such as cerebral infarction, cerebral hemorrhage and sub-arachnoid hemorrhage. Cardiac diseases and cerebrovascular diseases are the second and third causes of death in Japan, respectively. Such diseases cause substantial mortality and morbidity in many other countries as well, particularly in the more developed parts of the world. In the year 1998, sixty four patients per thousand in Japan visited the hospital regularly for hypertension according to research by the Ministry of Health and Welfare and hypertension is a primary cause of death.

20 [0003] As a countermeasure against the hypertension, a number of therapies have been developed, for instance development and use antihypertensive drugs such as diuretics, sympatholytic depressants, vasodilators and angiotensin converting enzyme inhibitors. These drugs are usually administered to patients diagnosed with a serious degree of hypertension.

[0004] On the other hand, treatments which generally improve health or contribute to a healthy lifestyle are indicated for patients with slight or serious hypertension. Such lifestyle changes or therapies include, dietary improvements or supplementation, stress reduction, therapeutic exercise and restriction of smoking and drinking. Improvement in dietary habits is of particular importance, as some foods may induce or contribute to hypertension. On the other hand selection of foods that provide hypotensive or anti-hypertensive effects may provide a positive overall benefit. Certain antihypertensive compounds or compositions have been identified and isolated from various food products.

30 [0005] While pharmaceutical medications and drugs generally act faster and exert a satisfactory anti-hypotensive effect than lifestyle or dietary changes, they often burden a patient with undesirable side-effects. On the other hand, while traditional food and nutritional products providing anti-hypertensive benefits are generally safe and free from substantial side-effects, the anti-hypertensive effects provided by these products may not always be satisfactory strong or efficacious, particularly in moderate or severe cases of hypertension, or the beneficial effects of such products may require a long time to develop.

35 [0006] Ferulic acid (3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid ($C_{10}H_{10}O_4$) is widely distributed in small amounts in plants. It may be isolated according to the method of Batesmith, Chem. & Ind. (London) 1954, 1457 or Klosserman, Muggli, J. Am. Chem. Soc. 81, 2188 (1959). It may also be prepared by chemical synthesis, for example, a process by a condensation reaction of vanillin and malonic acid, Journal of American Chemical Society, 74, 5346, (1952). Ferulic acid has the following chemical structure:

55 SUMMARY OF THE INVENTION

[0007] It is an object of the present invention to provide a drug, quasi-drug, pharmaceutical composition, or food or nutritional product which exerts a significantly high hypotensive effect, but which is safe, convenient to administer, and

easily assimilated. The present inventors have discovered that ferulic acid or a salt thereof exerts a remarkable anti-hypertensive or hypotensive effect.

[0008] Additionally, it has been found that an even higher hypotensive effect can be achieved by combining a diglyceride with a ferulic acid compound selected from the group consisting of ferulic acid, a salt of ferulic acid and a ferulic ester. Ferulic acid products either alone or in combination with diglycerides are advantageously incorporated into pharmaceutical, nutraceutical or other nutritional products, such as foods for treatment of diseases such as those associated with hypertension.

[0009] According to the present invention, there is thus provided a method of treating hypertension, which comprises administering ferulic acid or a salt thereof. The present invention also provides a method of treating hypertension, which comprises administering a composition containing:

- (a) at least one ferulic acid compound, for instance selected from the group consisting of ferulic acid, a salt of ferulic acid and a ferulic ester and
- (b) a diglyceride composition.

[0010] An inventive fat composition is provided comprising:

- (a) at least one ferulic acid compound selected from the group consisting of ferulic acid, a salt of ferulic acid and a ferulic ester and
- (b) a glyceride composition containing at least 15 % by weight of a diglyceride.

[0011] According to the present invention, a ferulic acid or its salt may be taken by itself as the only active antihypertensive ingredient in a pharmaceutical composition or food, or alternatively in a composition containing a diglyceride. Ferulic ester may be used in combination with a diglyceride composition, too. Either alone or in combination, such pharmaceutical and food compositions suppress elevated blood pressure and reduce the effects of hypertension, thus improving the prognosis of diseases associated with hypertension. Additionally, ferulic acid compounds may be combined with other conventional medications for hypertension, or other hypotensive agents. Therefore, the products according to the present invention are useful as drugs and food for preventing and treating hypertension.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Ferulic acid, its salts and esters used in the present invention may be extracted from natural substances, particularly plants, containing them or industrially manufactured by chemical synthesis. Incidentally, stereoisomers exist in ferulic acid and its derivatives. However, all the isomers may be used, and mixtures of different isomers may also be used.

[0013] Ferulic acid may be extracted from plants such as coffee, onion, Japanese radish, lemon, *Cnidium officinale* Makino, *Angelica acutiloba*, pine, *Captis japonica* Makino, asafetida, sweet potato, corn, barley and rice, with rice being particularly preferred. The term "rice" in the present specification includes green or dried products of grain such as *Oryza sativa* LINNE.

[0014] For the preparation of a ferulic ester, a rice bran oil is first prepared from rice bran, and then partitioned with hydrous ethanol and heat at room temperature under weakly alkaline conditions, thereby obtaining the ferulic ester in a hydrous ethanol fraction. Ferulic acid can be obtained by hydrolyzing the ferulic ester obtained by the above-described process with sulfuric acid with heating under pressure and purifying the resultant hydrolyzate or by culturing *Pseudomonas* in a medium containing clove oil from buds and leaves of *Syzygium aromaticum* MERRILL et PERRY by steam distillation, or eugenol obtained by purifying clove oil and subjecting the medium to isolation and purification.

[0015] The solubility of ferulic acid in water can be improved by providing it in the form of a salt, and its physiological effectiveness thus enhanced. No particular limitation is imposed on the salt of ferulic acid so far as it is a pharmaceutically acceptable salt. Examples of a basic substance used for forming such a salt include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide; inorganic bases such as ammonium hydroxide; basic amino acids such as arginine, lysine, histidine and ornithine; and organic bases such as monoethanolamine, diethanolamine and triethanolamine, with the alkali metal hydroxides and alkaline earth metal hydroxides being particularly preferred. The agents or fat compositions according to the present invention for preventing and treating hypertension may be formulated either by preparing such a salt and adding the salt to a composition composed of other components, or by separately adding ferulic acid and a salt-forming component to the above composition and forming a salt in the composition.

[0016] Examples of the alcohol moiety of the ferulic ester used in the present invention include linear or branched alkyl or alkenyl alcohols (preferably, linear or branched alkyl or alkenyl alcohols having 1 to 40 carbon atoms), aryl alcohols (preferably, aryl alcohols having 6 to 40 carbon atoms), terpene alcohols (particularly, monoterpene alcohol, ses-

quiterpene alcohol, diterpene alcohol and triterpene alcohol), sterol, trimethylsterol and plant sterol. More specifically, ethanol, oleyl alcohol, 2-ethylhexyl alcohol, allyl alcohol, cetyl alcohol, menthyl alcohol, phenol, benzyl alcohol, cholesterol, cycloartenol, 24-methylenecycloartenol, campesterol, β -sitosterol, stigmasterol, α -sitostanol, β -sitostanol and campestanol.

5 [0017] The combined use of a ferulic acid product such as one selected from the group consisting of ferulic acid, a salt of ferulic acid and a ferulic ester with a diglyceride permits further enhancing the hypotensive effect. As the diglyceride used herein, is preferred that having an acyl group having 8 to 24 carbon atoms, particularly 12 to 22 carbon atoms, for example, an acyl group derived from palmitic acid, stearic acid, oleic acid, linolic acid, linolenic acid, eicosapentaenoic acid or docosahexaenoic acid. The content of the unsaturated acyl group in the diglyceride is preferably at
10 least 55% by weight (hereinafter indicated merely by "%"), particularly at least 70% based on the weight of the whole acyl group. The unsaturated fatty acid is most preferably composed of 15 to 85% of oleic acid and 15 to 85% of linolic acid. The diglyceride of such a constitution is liquid near the bodily temperature and has an effect of enhancing the solubility of products such as ferulic acid, or a salt or ester thereof.

[0018] The diglyceride can be obtained in accordance with the process described in Japanese Patent Application
15 Laid-Open No. 300825/1992 or the like, for example, by an optional process such as a transesterification reaction of a triglyceride oil such as rapeseed oil, soybean oil, rice bran oil, corn oil, palm oil, olive oil, perilla oil, sesame oil, linseed oil or fish oil with glycerol, or an esterification reaction of a fatty acid derived from a oil or fat with glycerol. Reaction processes include a chemical reaction process making use of an alkali catalyst or the like and a biochemical reaction process making use of a fat-hydrolyzing enzyme such as a lipase, and the like. However, it is preferable to use the
20 biochemical reaction process to prevention of deterioration such as coloring.

[0019] In such a manner, the diglyceride is generally provided as a glyceride composition containing a monoglyceride and a triglyceride. The content of the diglyceride in the glyceride composition is preferably at least 15%, more preferably at least 55%, particularly preferably at least 80%. The hypotensive effect is enhanced by its combined use with ferulic acid, or a salt or ester thereof so far as the glyceride composition contains at least 15% of the diglyceride.
25 The diglyceride content in the glyceride composition is preferably at most 95% from the viewpoint of manufacturing profitability of the diglyceride, while the content of the monoglyceride is preferably at most 2%, with the remainder being the triglyceride.

[0020] The fat composition comprising the glyceride composition containing at least 15% of the diglyceride and ferulic acid, or a salt or ester of ferulic acid is novel and can be widely used as not only a medicine for preventing and treating hypertension, but also a food or nutritional material. The content of ferulic acid, or the salt or ester thereof in the fat
30 composition is preferably 0.01 to 50%, particularly preferably 0.1 to 20%.

[0021] The use of ferulic acid, or the salt or ester thereof or its combined use with a diglyceride can bring about an excellent hypotensive effect as demonstrated in the following Examples. These components are useful as drugs or nutraceuticals for preventing and treating hypertension and in food because they are highly safe.

35 [0022] Other hypotensive or anti-hypertensive drugs may be incorporated into the inventive compositions, nutraceuticals and foods and used in methods of treating hypertension, cardiac diseases and cerebrovascular diseases according to the present invention. Such drugs may include hypotensive drugs, for example, β -blockers, ACE inhibitors, Ca antagonists, diuretics, neurotropic drugs, etc.; various kinds of vitamins, for example, vitamin A, vitamin B1, B2, B6 and B12, vitamin C, vitamin D, vitamin E, etc.; and other active ingredients having a hypotensive or anti-hypertensive effect, for example, physiologically active lipids such as ω -3 type polyvalent unsaturated fatty acids such as α -linolenic acid, eicosapentaenoic acid and docosahexaenoic acid, or triglycerides containing any of these fatty acids as a constitutive fatty acid, etc., litchi, ginkgo, *Zizyphi fructus*, *Polygonatum sibiricum*, *cassiae semen*, shiitake, *Momordica grosvenori*, *Chrysanthemum morifolium*, *Plymnia sonchifolia*, mulberry leaves, banana leaves, *Curculigo orchoides*, plantago seed, *Corchorus olitorius*, etc.

45 [0023] When the composition according to the present invention is used as a medicine, a pharmaceutically acceptable carrier may be added to the above-described ingredients to prepare an oral or parenteral composition. Forms of the oral composition include tablets, granules, grains, pills, powder, capsules (including hard capsules and soft capsules), troches, chewable preparations and solutions (drinks). On the other hand, forms of the parenteral composition include those useful for intravenously administration, application to a mucous membrane or topical administration, such as injectable solutions, suppositories, and external skin care preparations.
50

[0024] When the composition according to the present invention is used as a food, the form of the food may be any form such as liquid, emulsion or paste food such as juice, margarine, mayonnaise, milk or curry; semisolid food such as jelly, gelatin or gumi; solid food such as gum, bean curd or nutritional supplements; or powdered food or edible oil, to which conventional food additives are added in addition to the active ingredients.

55 [0025] The effective dose of ferulic acid, or the salt or ester thereof used in the present invention per day for an adult (body weight: 60 kg) is preferably 0.001 to 100 g, particularly 0.01 to 10 g per day. The effective dose of the diglyceride is preferably 0.1 to 70 g, particularly 0.1 to 40 g per day for an adult (body weight: 60 kg).

Example 1: Composition of soft capsule

[0026]

Gelatin	70.00%
Glycerol	22.90
Methyl p-hydroxybenzoate	0.15%
Propyl p-hydroxybenzoate	0.51%
Water	6.44%
Total	100.00%

[0027] The soft capsule (oval form, weight: 150 mg) composed of the above composition was charged with soybean oil (450 mg) and ferulic acid (50 mg) in accordance with a conventional method to prepare a soft capsule preparation.

Example 2:

[0028] This example describes an emulsified drink containing a ferulic acid compound. The "oil and fat" component below comprises a glyceride composition (monoglyceride: 1.2%; diglyceride: 85.0%; and triglyceride: 13.8%) prepared from a fatty acid derived from rapeseed oil and glycerol using an enzymatic method.

Oil and fat	20.0%
Nonfat milk	3.5%
Protein (casein)	3.5%
Egg yolk lecithin	0.7%
Fructose	9.0%
Sodium ferulate	1.0%
Citric acid	0.1%
Ascorbic acid	0.1%
Perfume base	0.1%
Water	62.0%
Total	100.0%

[0029] The drink having the above composition was found to have high emulsion stability and has desirable or acceptable organoleptic properties.

Example 3:

[0030] This example describes a wheat product (cookies) comprising a ferulic acid compound. The "oil and fat" component below comprises a glyceride composition (monoglyceride: 1%; diglyceride: 82%; and triglyceride: 17%) prepared from a fatty acid derived from rapeseed oil and glycerol using an enzymatic method.

Oil and fat	15.0 g
Corn starch	20.0 g

EP 1 090 635 A2

(continued)

Wheat	50.0 g
Butter	5.0 g
Fructose	14.0 g
β -Sitosterol ferulate	1.0 g
Sodium chloride	0.5 g
Sodium bicarbonate	0.5 g
Water	10.0 g

[0031] Cookies composed of the above composition were baked in accordance with conventional methods.

Test Example 1: Comparison of short-term (1 hour) hypotensive effects induced by compositions containing ferulic acid compounds

i) Experimental materials and method:

(a) Animals used: Spontaneously Hypertensive Rats ("SHR"). Male.

[0032] The blood pressure of each spontaneous hypertensive rat (SHR) aged 15 weeks was preliminarily continuously measured for 7 days by means of a commercially available non-invasive sphygmomanometer (manufactured by Softron Co., Ltd.), thereby fully accustoming the rats to the sphygmomanometry, and an evaluation test was then started. All the rats were bred (in a breeding chamber in a rat zone) under conditions of a temperature of $25 \pm 1^\circ\text{C}$, a relative humidity of $55 \pm 10\%$ and a lighting time of 12 hours (from 7 a.m. to 7 p.m.).

(b) Administration method and dose:

[0033] Compositions for Control Group and Test Groups 1 to 6 were prepared in accordance with their corresponding formulations shown in Table 1. Oral administration was adopted as an administration method, and the respective compositions were forcibly administered by means of a metal-made stomach tube. The dose was determined to be 15 mL/kg.

Table 1

Component	Control Group	Test Group					
		1	2	3	4	5	6
Ferulic Acid	-	1.67	-	1.67	-	-	0.83
Sodium ferulate	-	-	1.67	-	1.67	-	-
Cycloartenol ferulate	-	-	-	-	-	1.67	0.83
Rapeseed oil	16.67	16.67	16.67	-	-	-	-
Diglyceride used in Example 2	-	-	-	16.67	16.67	16.67	16.67
Lecithin	0.08	0.08	0.08	0.08	0.08	0.08	0.08
Water	83.25	81.58	81.58	81.58	81.58	81.58	81.59
Total	100	100	100	100	100	100	100

(c) Testing method:

[0034] Six SHRs aged 15 weeks caused to fast overnight were used as a group. The systolic blood pressure (SBP) of a tail artery of each rat was measured before the oral administration of the composition (emulsion) and after 1 hour from the administration.

(d) Statistical processing method:

[0035] The thus-obtained test results were expressed by a mean and standard error to conduct a Student's t-test. A level of significance was defined as at most 5%.

(ii) Results:

[0036] The systolic blood pressures in each group before the administration and after 1 hour from the administration are shown in Table 2. As apparent from Table 2, the blood pressure was significantly reduced in the groups (Test Groups 1 and 2) administered with ferulic acid or the salt thereof compared with Control Group. In the groups (Test Groups 3 to 6) administered with any one of these compounds or the ferulic ester and the diglyceride in combination, the hypotensive effect was more markedly developed.

Table 2

	SBP (mmHg)	
	Before administration	After 1 hour from administration
Control Group	204.2 \pm 5.9	202.8 \pm 4.5
Test Group 1	206.0 \pm 1.3	180.4 \pm 2.5**
Test Group 2	207.1 \pm 4.2	181.6 \pm 4.1**
Test Group 3	207.2 \pm 3.0	165.9 \pm 3.6***,#
Test Group 4	209.5 \pm 4.4	168.1 \pm 2.5***,#
Test Group 5	208.5 \pm 3.5	163.2 \pm 1.2***,#
Test Group 6	205.5 \pm 5.3	161.4 \pm 4.1***,#

, *: There are significant differences at levels of significance of at most 1% and 0.1%, respectively.

#: There is a significant difference at a level of significance of at most 5% in other Test Groups as against Test Group 1.

Each value is expressed by mean \pm standard error.

Test Example 2: Comparison of long-term (4 weeks) hypotensive effects induced by compositions comprising ferulic acid compounds.

i) Experimental materials and method:

(a) Animal used: Spontaneous Hypertensive Rats ("SHR"). Male.

[0037] The blood pressure of each spontaneous hypertensive rat (SHR) aged 5 weeks was preliminarily continuously measured for 7 days by means of a commercially available non-invasive sphygmomanometer (manufactured by Softlon Co.), thereby fully accustoming the rats to the sphygmomanometry, and an evaluation test was then started. All the rats were bred (in a breeding chamber in a rat zone) under conditions of a temperature of $25 \pm 1^\circ\text{C}$, a relative humidity of $55 \pm 10\%$ and a lighting time of 12 hours (from 7 a.m. to 7 p.m.).

(b) Administration method and dose:

[0038] Rats of Test Groups 1 to 6 and Control group were provided as indicated in Test Example 1. Oral administration was adopted as an administration method, and the respective compositions were forcibly administered by means of a metal-made stomach tube. The dose was determined to be 10 mL/kg/day, and the administration was conducted for 5 days a week over 4 weeks.

(c) Testing method:

[0039] Six SHR_s aged 6 weeks were used as a group to measure the systolic blood pressure (SBP) of a tail artery of each rat before the test and after 4 weeks from the starting of the test.

(d) Statistical processing method:

[0040] The test results obtained were expressed by a mean and standard error and a Student's t-test was used to measure statistical significance of the results. A level of significance was defined as at most 5%.

(ii) Results:

[0041] Table 3 shows the systolic blood pressures (SBP) of each group before administration of a ferulic acid (or control) composition and after 4 weeks of five-times a week administration of these compositions. As apparent from Table 3, the rise of blood pressure was significantly inhibited in Test Groups 1 and 2 that were administered ferulic acid compositions compared with the Control Group. In Test Groups 3 to 6 administered with any one of the ferulic acid compounds or ferulic ester and the diglyceride in combination, the inhibitory effect on the rise of blood pressure was more markedly exhibited.

Table 3

	SBP (mmHg)	
	Before administration	After 4 weeks
Control Group	145.2 ± 3.5	204.2 ± 4.3
Test Group 1	145.2 ± 3.0	190.9 ± 2.8*
Test Group 2	145.1 ± 3.7	191.5 ± 3.6*
Test Group 3	145.3 ± 3.1	178.0 ± 3.5**,#
Test Group 4	145.6 ± 2.2	177.3 ± 4.0**,#
Test Group 5	145.1 ± 2.9	174.1 ± 2.1**,#
Test Group 6	145.0 ± 2.8	166.8 ± 4.5***,#

*, **, ***: There are significant differences at levels of significance of at most 5%, 1% and 0.1%, respectively.

#: There is a significant difference at a level of significance of at most 5% in other Test Groups as against Test Group 1.

Each value is expressed by mean ± standard error.

Modifications and other embodiments

[0042] Various modifications and variations of the described methods and compositions and concept of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed is not intended to be limited to such specific embodiments. Various modifications of the described modes for carrying out the invention which are obvious to those skilled in the chemical, medical or pharmaceutical arts or related fields are intended to be within the scope of the following claims.

Incorporation by Reference

[0043] Each reference, patent application or patent publication cited by or referred to in this disclosure is incorporated by reference in its entirety. Any patent document to which this application claims priority is also incorporated by reference in its entirety. Specifically, the foreign priority documents which are corresponding Japanese Patent Applications No. 1999-268461 filed September 22, 1999, No. 2000-107957 filed April 10, 2000 and No. 2000-230463 filed July 31, 2000 are hereby incorporated by reference.

Claims

1. A composition comprising ferulic acid or a salt thereof in a form and in amount suitable for treating a subject suffering from hypertension.
- 5 2. A composition comprising:
 - (a) at least one ferulic acid compound selected from the group consisting of ferulic acid, a salt of ferulic acid and a ferulic ester, and
 - 10 (b) a diglyceride composition.
3. The composition of Claim 2, wherein said diglyceride composition comprises at least 15 % by weight of a diglyceride.
- 15 4. The composition of Claim 1 or 2, further comprising an emulsifier.
5. The composition of Claim 1 or 2, further comprising a second pharmaceutically active compound.
- 20 6. The composition of Claim 5, wherein said pharmaceutically active compound is anti-hypertensive compound, a compound used to treat cardiac disease or compound used to treat a cerebrovascular disease.
7. A food or nutritional product comprising the composition of Claim 1 or 2.
- 25 8. A method of treating hypertension comprising administering the composition as defined in any one of the claims 1 to 6, to a subject in need of treatment.
9. A method of treating a cardiac disease or a cerebrovascular disease comprising administering the composition, as defined in any one of the claims 1 to 6, to a subject in need of treatment.
- 30 10. Use of a composition as defined in any one of the claims 1 to 6, for preparing a medicament for treating a cardiac disease or hypertension.

35

40

45

50

55

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 090 635 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
27.02.2002 Bulletin 2002/09

(43) Date of publication A2:
11.04.2001 Bulletin 2001/15

(21) Application number: 00120170.6

(22) Date of filing: 22.09.2000

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.09.1999 JP 26846199
31.07.2000 JP 2000230463

(71) Applicant: Kao Corporation
Tokyo 103-8210 (JP)

(72) Inventors:
• Suzuki, Atsushi
Ichikai-machi, Haga-gun 321-3497 (JP)
• Ochiai, Ryuji
Ichikai-machi, Haga-gun 321-3497 (JP)
• Tokimitsu, Ichiro
Ichikai-machi, Haga-gun 321-3497 (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München (DE)

(54) Use of ferulic acid for treating hypertension

(57) A method for treating hypertension, a cardiac disease, or a cerebrovascular disease comprising administration of ferulic acid or a salt thereof, to a subject in need of treatment. Ferulic acid or salt thereof itself may be used as the only active antihypertensive ingredient in a therapeutic composition of the present inven-

tion. Alternatively, the therapeutic composition may comprise a diglyceride composition in combination with at least one compound selected from ferulic acid, a salt thereof and a ferulic ester.

EP 1 090 635 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 12 0170

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
E	WO 00 61131 A (HUH SUNG OH ;KIM YUNG HI (KR); BIOSYNERGEN INC (KR); SCIGENIC CO L) 19 October 2000 (2000-10-19) * page 2, line 6,7 * * page 7, line 23 * * page 8, line 12 - line 22 * * claims 1-3,8,9 * * examples 3,5,6 *	1,4-7,9,10	A61P9/00 A61P9/10 A61P9/12 A61K9/00 A61K9/48 A61K31/192 A61K47/14 A61K47/44 A61K45/06
E	WO 00 78162 A (KONISHI YOSHIHIRO ;KAWAI SHIGERU (JP); KAO CORP (JP)) 28 December 2000 (2000-12-28) * page 8, line 20 - page 9, line 5 * * page 9, line 16 - line 25 * * page 10, line 3 - line 5 * * claims 1,5-7 *	2-4,7	
X	US 4 842 859 A (LIU YAGUANG) 27 June 1989 (1989-06-27) * column 2, line 24 - line 37 * * column 3, line 2 - line 4 * * claims 3,4 *	1,2,5-7,9,10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K A61P
INCOMPLETE SEARCH The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search THE HAGUE		Date of completion of the search 20 December 2001	Examiner van der Kooij, M
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03/02 (P04007)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 00 12 0170

Although claims 8 and 9 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched incompletely:
5,6,8-10

Reason for the limitation of the search:

Present claims 5, 6, and 8-10 relate to a composition containing further compounds which actually are not well-defined: "a second pharmaceutically active compound", "an anti-hypertensive compound", "a compound used to treat cardiac disease" and "a compound used to treat a cerebrovascular disease". The claims cover all compounds having this characteristic or property whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely compositions containing ferulic acid, its salts and ferulic esters in relation to their use in the treatment of hypertension (page 1, first paragraph; page 2, third and fourth paragraph; examples).



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 12 0170

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 96 38047 A (UNILEVER PLC ; UNILEVER NV (NL); LIEVENSE LOURUS CORNELIS (NL)) 5 December 1996 (1996-12-05) * page 1, line 3 - line 7 * * page 8, line 3 - line 26 * * page 9, line 21 - line 26 * * page 10, line 20 - page 11, line 12 * * claims 1-10 * * examples 5-7 *	1,2,4-7, 9,10	
X	US 4 707 472 A (AOKI HIDEMI ET AL) 17 November 1987 (1987-11-17) * column 1, line 18 - line 23 *	1,8-10	
X	DATABASE WPI Section Ch, Week 198641 Derwent Publications Ltd., London, GB; Class A96, AN 1986-267860 XP002180159 & JP 61 194022 A (ZERIA SHINYAKU KOGYO KK) , 28 August 1986 (1986-08-28) * abstract *	1,8-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	PATENT ABSTRACTS OF JAPAN vol. 007, no. 268 (C-197), 30 November 1983 (1983-11-30) & JP 58 150600 A (TOMOTAROU TSUCHIYA), 7 September 1983 (1983-09-07) * abstract *	2	

EPO FORM 1503 03.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 12 0170

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-12-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0061131	A	19-10-2000	AU	4147800 A	14-11-2000
			WO	0061131 A1	19-10-2000
WO 0078162	A	28-12-2000	JP	2001000138 A	09-01-2001
			WO	0078162 A2	28-12-2000
US 4842859	A	27-06-1989	US	5108750 A	28-04-1992
			US	4906471 A	06-03-1990
WO 9638047	A	05-12-1996	AU	1347500 A	20-04-2000
			AU	1347600 A	20-04-2000
			AU	6003796 A	18-12-1996
			BR	9608914 A	02-03-1999
			CA	2222771 A1	05-12-1996
			DE	69606638 D1	16-03-2000
			DE	69606638 T2	20-07-2000
			DK	828434 T3	13-06-2000
			WO	9638047 A1	05-12-1996
			EP	0828434 A1	18-03-1998
			EP	0960567 A2	01-12-1999
			EP	0962150 A2	08-12-1999
			ES	2142589 T3	16-04-2000
			JP	11506324 T	08-06-1999
			AU	1347200 A	06-04-2000
			AU	1347300 A	06-04-2000
			AU	1347400 A	06-04-2000
US 4707472	A	17-11-1987	JP	61040298 A	26-02-1986
			EP	0216927 A1	08-04-1987
			WO	8600312 A1	16-01-1986
JP 61194022	A	28-08-1986	JP	1767761 C	11-06-1993
			JP	4056839 B	09-09-1992
JP 58150600	A	07-09-1983	NONE		

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82